IMMUTEP Ltd (IMMP) Form 6-K — Oct 30, 2026
Immutep's Q1 FY27 report confirms the company is pivoting its lead asset efti toward registration-directed trials in HNSCC (CPS <1) and neoadjuvant soft tissue sarcoma, with study starts targeted for H2 CY27, following the Phase III TACTI-004 futility failure in lung cancer. The root cause analysis blames the TACTI-004 failure on structural differences between 2,000 L scale efti used in the failed trial versus 200 L scale efti used in prior successful studies, and a new 200 L manufacturing run has been contracted. Positive data continues elsewhere: EFTISARC-NEO met its primary endpoint (51.5% tumour hyalinization vs 35% target) and INSIGHT-003 showed a 30.9-month median OS in 1L NSCLC.
Key figures
- Cash Position
- A$48.50 million
- Cash runway
- well into H1 CY28
- Staff costs q
- A$2.4 million
- Ads ratio change
- 1 ADS = 200 ordinary shares (from 10), effective 28 Sep 2026
- Next trial start
- H2 CY27
- Aust rd tax rebate
- A$0.86 million
- French cir payment
- EUR 1.36 million (~A$2.16 million)
- Net cash used ga q
- A$1.2 million
- Net cash used rd q
- A$16.5 million
- Insight 003 patients
- 51
- Insight 003 median os
- 30.9 months
- Rd cash prior quarter
- A$22.0 million
- Net cash used operating q
- A$19.1 million
- Eftisarc neo hyalinization
- 51.5% median vs 35% target (p<0.001), N=38
- Estimated quarters funding formula
- 2.53
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.